Ardelyx, Inc. (ARDX) Stock Price
ARDXStock
$3.09−38.81%52W
Market Cap$797.80M
P/E—
PEG Ratio—
Div yield—
Beta0.73
ARDX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-61.09%
Price vs S&P 500 (4W)-10.39%
VGM Score51.10
ARDX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.05 | -$0.07 | -41.44%(-$0.02) | |
| Q1 2026 | -$0.14 | -$0.15 | -5.00%(-$0.01) | |
| Q4 2025 | $0.01 | $0.00 | -100.00%(-$0.01) | |
| Q3 2025 | -$0.07 | $0.00 | +100.00%(+$0.07) | |
| Q2 2025 | -$0.14 | -$0.08 | +41.55%(+$0.06) |
ARDX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.47
4.50
4.50
4.50
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
ARDXArdelyx, Inc. | C | B | D | 1.7x | 16.8% | 94.4% | — | $3.09 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Ardelyx, Inc.
Ardelyx Inc is a biopharmaceutical company developing first-in-class medicines for unmet medical needs using a proprietary platform designed to minimize side effects and drug-drug interactions. The company's marketed products include IBSRELA (tenapanor) for irritable bowel syndrome with constipation in adults, and XPHOZAH (tenapanor) for reducing serum phosphorus in dialysis patients with chronic kidney disease who have inadequate response to or intolerance of phosphate binders.